Table 1

Baseline characteristics of total pooled phase 3 population and low complement/anti-dsDNA-positive subgroup

Total phase 3 pooled (n=1684)Low complement/anti-dsDNA positive (n=876)
Mean SELENA–SLEDAI score ±SD9.7±3.810.8±3.8
SELENA–SLEDAI ≥10, %52.165.5
Proteinuria (≥2 g/24 h), %5.98.8
Anti-dsDNA (≥30 IU/ml), %69.4100
IgG (>16.2 g/l), %44.253.0
Low C3 (<90 mg/dl), %45.075.3
Low C4 (<16 mg/dl), %56.191.4
Corticosteroid use, %86.391.4
>7.5 mg/day, %58.063.5
Immunosuppressant use, %48.753.4
Mean SLICC damage index score ±SD0.8±1.20.7±1.1
Mean PGA score ±SD1.4±0.51.4±0.5
  • C, complement; Ig, immunoglobulin; PGA, Physician's Global Assessment; SELENA–SLEDAI, Safety Of Estrogens In Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index; SLICC, Systemic Lupus International Collaborating Clinics.